10x Genomics
TXG
Market cap $1.02B

8.32 USD

-0.76

8.37%

At close May 21, 4:00 PM EDT

Pre-market

8.24

-0.08

0.96%

1 day

-8.37%

5 days

-7.66%

1 month

8.33%

3 months

-23.67%

6 months

-37.40%

Year to date

-41.37%

1 year

-65.26%

5 years

-89.05%

10 years

-84.23%

About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Employees: 1,306

Healthcare Health Information Services

0

Funds holding %

of 7,245 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

81% more call options, than puts

Call options by funds: $2.66M | Put options by funds: $1.47M

42% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 74

7.38% more ownership

Funds ownership: 97.7% [Q4 2024] → 105.08% (+7.38%) [Q1 2025]

7% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 45

0% less funds holding

Funds holding: 270 [Q4 2024] → 269 (-1) [Q1 2025]

34% less capital invested

Capital invested by funds: $1.5B [Q4 2024] → $993M (-$509M) [Q1 2025]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6.50

22%

downside

Avg. target

$12.69

52%

upside

High target

$18

116%

upside

8 analyst ratings

5 positive

63%

2 neutral

25%

1 negative

13%

Morgan Stanley Tejas Savant	116%upside $18	Overweight Maintained	19 May 2025
Stephens & Co. Mason Carrico	68%upside $14	Overweight Reiterated	15 May 2025
UBS Dan Leonard	44%upside $12	Neutral Maintained	13 May 2025
Goldman Sachs Matthew Sykes	22%downside $6.50	Sell Maintained	12 May 2025
Canaccord Genuity Kyle Mikson	80%upside $15	Buy Maintained	12 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about TXG published over the past 30 days

Zacks Investment Research

10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know

10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

PLEASANTON, Calif. , May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and disputes between the two companies.

10x Genomics Announces Patent Litigation Settlement Agreement with Bruker

Zacks Investment Research

Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade

10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Cassie Corneau – Senior Director, Investor Relations Serge Saxonov – Chief Executive Officer and Co-Founder Adam Taich – Chief Financial Officer Conference Call Participants Patrick Donnelly – Citi Kyle Mikson – Canaccord Genuity Madeline Mollman – Wolfe Research Matt Sykes – Goldman Sachs Kyle Boucher – TD Cowen Operator Ladies and gentlemen, thank you so much for standing by and welcome to 10x Genomics First Quarter 2025 Earnings Conference Call. Please note that this call is being recorded.

10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

10x Genomics (TXG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

10x Genomics Reports First Quarter 2025 Financial Results

PLEASANTON, Calif. , May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025.

10x Genomics Reports First Quarter 2025 Financial Results

Zacks Investment Research

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

PLEASANTON, Calif. , April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, at 11:20 a.m.

10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

Vizgen Announces End of Litigation with 10x Genomics and Harvard University

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #neuroscience--Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an open letter in response to the settlement of litigation between Vizgen, Harvard University and 10X Genomics in the United States District Court for the District of Delaware. Dear Customers, Researchers and Friends of Vizgen: On February 5th, we secured an important settlement putting an end to litigation, including.

Vizgen Announces End of Litigation with 10x Genomics and Harvard University

See News Rankings

Charts implemented using Lightweight Charts™